As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Spyre Therapeutics, Inc. The largest reported stake is Fairmount Funds Management LLC's, at 9.99%. 12 filings are on record since July 16, 2025 (Schedule 13D/A, October 9, 2026).
Sell to companies like Spyre Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fairmount Funds Management LLC · Sole voting: 0 · Shared voting: 9,354,200 · Sole dispositive: 0 · Shared dispositive: 9,354,200 · SCHEDULE 13D/A, 2026-10-09
- · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 4,457,450 · Shared voting: 0 · Sole dispositive: 4,457,450 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-01
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 4,319,496 · Sole dispositive: 0 · Shared dispositive: 4,319,496 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 4,251,996 · Sole dispositive: 0 · Shared dispositive: 4,251,996 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Fairmount Funds Management LLC · Percent: 9.99% · SCHEDULE 13D/A
Spyre Therapeutics, Inc. has 12 Schedule 13D or 13G filings on record since 2025-07-16. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 9.99% | 9,354,200 | SCHEDULE 13D/A, 2026-10-09 | 2026-10-07 |
| BlackRock, Inc. | 6.6% | 3,962,635 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Paradigm BioCapital Advisors LP | 5.1% | 4,457,450 | SCHEDULE 13G, 2026-10-01 | 2026-09-24 |
| Perceptive Advisors LLC | 4.9% | 4,319,496 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| RTW Investments, LP | 4.8% | 4,251,996 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Tang Capital Management, LLC | 2.4% | 1,892,200 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Spyre Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Spyre Therapeutics, Inc. and the records around it.
Spyre Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026), Apogee Therapeutics, Inc. (Sep 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026), Arcellx, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Spyre Therapeutics, Inc.
Get an email when Spyre Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Spyre Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Spyre Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Spyre Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 0 | 9,354,200 | 0 | 9,354,200 | SCHEDULE 13D/A, 2026-10-09 |
| Fairmount Healthcare Fund II L.P. | 0 | 9,354,200 | 0 | 9,354,200 | SCHEDULE 13D/A, 2026-10-09 |
| Harwin Peter Evan | 520,361 | 9,665,600 | 520,361 | 9,665,600 | SCHEDULE 13D/A, 2026-10-09 |
| Kiselak Tomas | 520,361 | 9,665,600 | 520,361 | 9,665,600 | SCHEDULE 13D/A, 2026-10-09 |
| Paradigm BioCapital Advisors LP | 4,457,450 | 0 | 4,457,450 | 0 | SCHEDULE 13G, 2026-10-01 |
| Paradigm BioCapital Advisors GP LLC | 4,457,450 | 0 | 4,457,450 | 0 | SCHEDULE 13G, 2026-10-01 |
| Senai Asefaw, M.D. | 4,457,450 | 0 | 4,457,450 | 0 | SCHEDULE 13G, 2026-10-01 |
| Paradigm BioCapital International Fund Ltd. | 3,928,646 | 0 | 3,928,646 | 0 | SCHEDULE 13G, 2026-10-01 |
| Perceptive Advisors LLC | 0 | 4,319,496 | 0 | 4,319,496 | SCHEDULE 13G/A, 2026-08-14 |
| Joseph Edelman | 0 | 4,319,496 | 0 | 4,319,496 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 4,319,496 | 0 | 4,319,496 | SCHEDULE 13G/A, 2026-08-14 |
| RTW Investments, LP | 0 | 4,251,996 | 0 | 4,251,996 | SCHEDULE 13G/A, 2026-08-14 |
| Roderick Wong | 0 | 4,251,996 | 0 | 4,251,996 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Spyre Therapeutics, Inc. by CUSIP 00773J202 and gives its principal executive office as 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (SCHEDULE 13D/A, 2026-10-09).
What the percentages are based on
See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 88,173,762 shares of Common Stock outstanding as of July 28, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on August 4, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G, 2026-10-01
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 6.6% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 5.08% | SCHEDULE 13G |
| 2025-10-17 | Fairmount Funds Management LLC | 9.99% | SCHEDULE 13D/A |
| 2026-02-17 | Tang Capital Management, LLC | 2.4% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-20 | Fairmount Funds Management LLC | 9.99% | SCHEDULE 13D/A |
| 2026-04-22 | Perceptive Advisors LLC | 5% | SCHEDULE 13G |
| 2026-06-23 | Fairmount Funds Management LLC | 9.99% | SCHEDULE 13D/A |
| 2026-08-14 | Perceptive Advisors LLC | 4.9% | SCHEDULE 13G/A |
| 2026-08-14 | RTW Investments, LP | 4.8% | SCHEDULE 13G/A |
| 2026-10-01 | Paradigm BioCapital Advisors LP | 5.1% | SCHEDULE 13G |
| 2026-10-09 | Fairmount Funds Management LLC | 9.99% | SCHEDULE 13D/A |
Questions about who owns Spyre Therapeutics, Inc.
Who owns Spyre Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Spyre Therapeutics, Inc.: Fairmount Funds Management LLC (9.99%, Schedule 13D/A, filed 2026-10-09), BlackRock, Inc. (6.6%, Schedule 13G/A, filed 2025-07-16) and Paradigm BioCapital Advisors LP (5.1%, Schedule 13G, filed 2026-10-01).
Who are the largest shareholders of Spyre Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Spyre Therapeutics, Inc. on this page are Fairmount Funds Management LLC (9.99%), BlackRock, Inc. (6.6%) and Paradigm BioCapital Advisors LP (5.1%).
When did Fairmount Funds Management LLC buy into Spyre Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-10-17, reporting 9.99%; its latest, Schedule 13D/A filed 2026-10-09, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Spyre Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.